Research programme: anti-cancer therapeutics - Institut du Cancer de Montpellier/Onward Therapeutics
Alternative Names: Oncometabolism therapeuticsLatest Information Update: 25 Jun 2021
At a glance
- Originator Institut du Cancer de Montpellier - Val d'Aurelle
- Developer Onward Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 08 Jun 2021 Onward Therapeutics and Institut du Cancer de Montpellier entered an agreement for development of anticancer therapeutics
- 08 Jun 2021 Early research in Cancer in France (unspecified route) prior to June 2021
- 08 Jun 2021 Early research in Cancer in Switzerland (unspecified route) prior to June 2021